期刊文献+

多西紫杉醇联合强的松治疗激素难治性前列腺癌的疗效 被引量:1

Efficacy of combined use of docetaxel and prednisone in treating hormone-refractory prostate cancer
原文传递
导出
摘要 目的探讨多西紫杉醇联合强的松治疗激素难治性前列腺癌的临床疗效。方法 64例激素难治性前列腺癌患者随机分为治疗组(32例)和对照组(32例)。两组均每3周(1个治疗周期)用多西紫杉醇75mg/m2静脉滴注1h。治疗组加用强的松5mg,每天2次。比较疗效及不良反应。结果 64例中,5例完成了8个周期治疗,15例6个周期,42例4个周期,2例1个周期。治疗组化疗后总有效率为87.5%,明显高于对照组的56.2%(P<0.05)。治疗组疼痛减轻效果也优于对照组。两组不良反应相仿(P>0.05)。结论多西紫杉醇联合强的松治疗激素难治性前列腺癌疗效确切,明显改善患者生活质量。 Objective To explore the effect of docetaxel combined with prednisone on hormone- refractory prostate cancer(HRPC). Methods Sixty-four HRPC patients were equally randomized into two groups. The patients in group A were treated with infusion of doeetaxel 75 mg/m2 in I hour every 3 weeks as one cycle and those in group B were given additional prednisone 5 mg twice a day for 3 weeks. The efficacy and adverse responses were compared. Results Of 64 cases, 5 eases completed 8 treatment cycles,25 cases 6 cycles, 42 cases 4 cycles and 2 cases 1 cyle. The total effectiveness rate was higher in group A than that in group B (87.5% vs. 56.2%) (P〈0. 05). The decrease of pain score in group A was more than that in group B. There was no significant difference in adverse responses between two groups. Conclusion The docetaxel combined with prednisone is effective in treating HRPC with remarkable improvement of life quality.
出处 《江苏医药》 CAS CSCD 北大核心 2012年第18期2174-2175,共2页 Jiangsu Medical Journal
关键词 多西紫杉醇 前列腺癌 强的松 Docetaxel Prostate cancer Prednisone
  • 相关文献

参考文献5

二级参考文献19

  • 1叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:170
  • 2Newman L A, Lee C T, Parekh L P, et al. Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee [J]. Cancer, 2006, 106( 1 ) : 188-195.
  • 3Mendiratta P, Armstrong A J, George D J. Current standard and investigational approaches to the management of hormone-refractory prostate cancer [J]. Rev Urol, 2007, 9 (Suppl 1 ) :S9-S19.
  • 4Fennely D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paelitaxel administered weekly in patients with relapsed ovarian cancer[J]. J Clin Oncol, 1997, 15(2): 187- 192.
  • 5Hainsworth J, Burris H, Erland J, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer [J]. J Olin Oncol, 1998, 16(6) : 2164-2168.
  • 6Berry W, Dakhil S, Gregurich M A, et al. Phase Ⅱ trial of singleagent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate [J]. Semin Oncol, 2001, 28 (4 Suppl 15) :8-15.
  • 7Tester W, Ackler J, Tijani L, et al. Phase I / II study of weekly docetaxel and vinblastine in the treatment of metastatic hormonerefractory prostate carcinoma[J]. Cancer J, 2006, 12(4) :299-304.
  • 8李鸣,孙光,贺大林,等.前列腺癌诊断治疗指南//那彦群.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2006:53-95.
  • 9Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plis prednisone for advanced prostate cancer. N Engl J Med ,2004, 351 : 1502 - 1512.
  • 10Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. 2006.

共引文献15

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部